Skip to main content
Top
Published in: AIDS Research and Therapy 1/2015

Open Access 01-12-2015 | Research

HIV-1 transmitted drug resistance mutations among antiretroviral therapy-Naïve individuals in Surabaya, Indonesia

Authors: Tomohiro Kotaki, Siti Qamariyah Khairunisa, Adiana Mutamsari Witaningrum, Muhammad Qushai Yunifiar M, Septhia Dwi Sukartiningrum, Muhammad Noor Diansyah, Retno Pudji Rahayu, Nasronudin, Masanori Kameoka

Published in: AIDS Research and Therapy | Issue 1/2015

Login to get access

Abstract

Background

The emergence of transmitted drug resistance (TDR) compromises the effect of antiretroviral therapy (ART), resulting in treatment failure of human immunodeficiency virus (HIV) disease. Although more than a decade has passed since ART was introduced into Indonesia, information on TDR is limited. Here, a genotypic study of TDR among ART-naïve individuals was conducted in Surabaya, Indonesia.

Method

HIV-1 seropositive participants were recruited from the communities of commercial sex workers and intravenous drug users as well as from the university teaching hospital in Surabaya. Protease (PR) and reverse transcriptase (RT) genes were sequenced in order to conduct HIV-1 subtyping and phylogenetic analysis and to detect TDR. TDR was defined as the presence of at least one surveillance drug resistance mutation on the WHO list or major drug resistance mutations in the International AIDS Society-USA panel.

Result

Fifty two and 47 of the PR and RT genes, respectively, were successfully sequenced in the 58 samples. HIV-1 subtyping revealed that 86.3% (50/58) of the sequenced samples were classified as CRF01_AE, 8.6% as subtype B, 3.4% as B/CRF01_AE, and 1.7% as A/G/CRF01_AE. TDR of PR inhibitors was not detected in this study. In contrast, TDR of RT inhibitors was detected in 4.3% (2/47) of samples. In addition, minor drug resistance mutations were detected in 98.1% (51/52) and 12.8% (6/47) of PR and RT genes, respectively.

Conclusion

This study clarified the predominance of the CRF01_AE strain in Surabaya, Indonesia. The prevalence of TDR was below 5%, indicating that the currently available first-line regimen is still effective in Surabaya. However, the prevalence might be underestimated since we detected only major population of HIV-1 in individuals. Therefore, continuous surveillance is required in order to detect the emergence of TDR in the early phase.
Appendix
Available only for authorised users
Literature
1.
go back to reference Popp D, Fisher JD. First, do no harm: a call for emphasizing adherence and HIV prevention interventions in active antiretroviral therapy programs in the developing world. AIDS. 2002;16:676–8.CrossRefPubMed Popp D, Fisher JD. First, do no harm: a call for emphasizing adherence and HIV prevention interventions in active antiretroviral therapy programs in the developing world. AIDS. 2002;16:676–8.CrossRefPubMed
2.
go back to reference Pillay D, Bhaskaran K, Jurriaans S, Prins M, Masquelier B, Dabis F, et al. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS. 2006;20:21–8.CrossRefPubMed Pillay D, Bhaskaran K, Jurriaans S, Prins M, Masquelier B, Dabis F, et al. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS. 2006;20:21–8.CrossRefPubMed
3.
go back to reference Sohn AH, Srikantiah P, Sungkanuparph S, Zhang F. Transmitted HIV drug resistance in Asia. Curr Opin HIV AIDS. 2013;8:27–33.CrossRefPubMed Sohn AH, Srikantiah P, Sungkanuparph S, Zhang F. Transmitted HIV drug resistance in Asia. Curr Opin HIV AIDS. 2013;8:27–33.CrossRefPubMed
5.
go back to reference Trotter AB, Hong SY, Srikantiah P, Abeyewickreme I, Bertagnolio S, Jordan MR. Systematic review of HIV drug resistance in Southeast Asia. AIDS Rev. 2011;15:162–70. Trotter AB, Hong SY, Srikantiah P, Abeyewickreme I, Bertagnolio S, Jordan MR. Systematic review of HIV drug resistance in Southeast Asia. AIDS Rev. 2011;15:162–70.
9.
go back to reference Fibriani A, Wisaksana R, Indrati A, Hartantri Y, van de Vijver D, Schutten M, et al. Virological failure and drug resistance during first line anti-retroviral treatment in Indonesia. J Med Virol. 2013;85:1394–401.CrossRefPubMed Fibriani A, Wisaksana R, Indrati A, Hartantri Y, van de Vijver D, Schutten M, et al. Virological failure and drug resistance during first line anti-retroviral treatment in Indonesia. J Med Virol. 2013;85:1394–401.CrossRefPubMed
10.
go back to reference Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer RW, et al. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med. 2013;21:6–14.PubMed Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer RW, et al. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med. 2013;21:6–14.PubMed
11.
go back to reference Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4:e4724.CrossRefPubMedPubMedCentral Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4:e4724.CrossRefPubMedPubMedCentral
12.
go back to reference Auwanit W, Isarangkura-Na-Ayuthaya P, Kasornpikul D, Ikuta K, Sawanpanyalert P, Kameoka M. Detection of drug resistance-associated and background mutations in human immunodeficiency virus type 1 CRF01_AE protease and reverse transcriptase derived from drug treatment-naive patients residing in central Thailand. AIDS Res Hum Retroviruses. 2009;25:625–31.CrossRefPubMed Auwanit W, Isarangkura-Na-Ayuthaya P, Kasornpikul D, Ikuta K, Sawanpanyalert P, Kameoka M. Detection of drug resistance-associated and background mutations in human immunodeficiency virus type 1 CRF01_AE protease and reverse transcriptase derived from drug treatment-naive patients residing in central Thailand. AIDS Res Hum Retroviruses. 2009;25:625–31.CrossRefPubMed
13.
go back to reference SahBandar IN, Takahashi K, Motomura K, Djoerban Z, Firmansyah I, Kitamura K, et al. The Indonesian variants of CRF33_01B: near-full length sequence analysis. AIDS Res Hum Retroviruses. 2010;27:97–102.CrossRefPubMed SahBandar IN, Takahashi K, Motomura K, Djoerban Z, Firmansyah I, Kitamura K, et al. The Indonesian variants of CRF33_01B: near-full length sequence analysis. AIDS Res Hum Retroviruses. 2010;27:97–102.CrossRefPubMed
14.
go back to reference Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The world health organization’s global strategy for prevention and assessment of HIV drug resistance. Antivir Ther. 2008;2(13):1–13. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The world health organization’s global strategy for prevention and assessment of HIV drug resistance. Antivir Ther. 2008;2(13):1–13.
15.
go back to reference Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008;2(13):25–36. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008;2(13):25–36.
16.
go back to reference Castro H, Pillay D, Cane P, Asboe D, Cambiano V, Phillips A. Dunn DT; UK collaborative group on HIV drug resistance: persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis. 2013;208:1459–63.CrossRefPubMedPubMedCentral Castro H, Pillay D, Cane P, Asboe D, Cambiano V, Phillips A. Dunn DT; UK collaborative group on HIV drug resistance: persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis. 2013;208:1459–63.CrossRefPubMedPubMedCentral
17.
go back to reference Simen BB, Simons JF, Hullsiek KH, Novak RM, MacArthur RD, Baxter JD, et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naïve patients significantly impact treatment outcomes. J Infect Dis. 2009;199:693–701.CrossRefPubMed Simen BB, Simons JF, Hullsiek KH, Novak RM, MacArthur RD, Baxter JD, et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naïve patients significantly impact treatment outcomes. J Infect Dis. 2009;199:693–701.CrossRefPubMed
18.
go back to reference Lataillade M, Chiarella J, Yang R, Schnittman S, Wirtz V, Uy J, et al. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study. PLoS One. 2010;5:e10952.CrossRefPubMedPubMedCentral Lataillade M, Chiarella J, Yang R, Schnittman S, Wirtz V, Uy J, et al. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study. PLoS One. 2010;5:e10952.CrossRefPubMedPubMedCentral
19.
go back to reference Kotaki T, Khairunisa SQ, Sukartiningrum SD, Arfijanto MV, Utsumi T, Normalina I, et al. High prevalence of HIV-1 CRF01_AE viruses among female commercial sex workers residing in Surabaya. Indonesia PLoS One. 2013;8:e82645.CrossRefPubMed Kotaki T, Khairunisa SQ, Sukartiningrum SD, Arfijanto MV, Utsumi T, Normalina I, et al. High prevalence of HIV-1 CRF01_AE viruses among female commercial sex workers residing in Surabaya. Indonesia PLoS One. 2013;8:e82645.CrossRefPubMed
20.
go back to reference Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S, et al. Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011;28:2731–9.CrossRefPubMedPubMedCentral Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S, et al. Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011;28:2731–9.CrossRefPubMedPubMedCentral
21.
go back to reference Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol. 1980;16:111–20.CrossRefPubMed Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol. 1980;16:111–20.CrossRefPubMed
22.
go back to reference Saitou N, Nei M. The neighbor-joining method: a new method forreconstructing phylogenetic trees. Mol Biol Evol. 1987;4:406–25.PubMed Saitou N, Nei M. The neighbor-joining method: a new method forreconstructing phylogenetic trees. Mol Biol Evol. 1987;4:406–25.PubMed
23.
go back to reference Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution. 1985;39:783–91.CrossRef Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution. 1985;39:783–91.CrossRef
24.
go back to reference Bulla I, Schultz AK, Meinicke P. Improving hidden markov models for classification of human immunodeficiency virus-1 subtypes through linear classifier learning. Stat Appl Genet Mol Biol. 2012. 11: doi:10.2202/1544-6115.1680 Bulla I, Schultz AK, Meinicke P. Improving hidden markov models for classification of human immunodeficiency virus-1 subtypes through linear classifier learning. Stat Appl Genet Mol Biol. 2012. 11: doi:10.2202/1544-6115.1680
Metadata
Title
HIV-1 transmitted drug resistance mutations among antiretroviral therapy-Naïve individuals in Surabaya, Indonesia
Authors
Tomohiro Kotaki
Siti Qamariyah Khairunisa
Adiana Mutamsari Witaningrum
Muhammad Qushai Yunifiar M
Septhia Dwi Sukartiningrum
Muhammad Noor Diansyah
Retno Pudji Rahayu
Nasronudin
Masanori Kameoka
Publication date
01-12-2015
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2015
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/s12981-015-0046-y

Other articles of this Issue 1/2015

AIDS Research and Therapy 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.